Mycophenolic acid interaction with cyclosporine and tacrolimus in vitro and in vivo: Evaluation of additive effects on rat blood lymphocyte function

Therapeutic Drug Monitoring

Volumn 27, Issue 2, 2005, Pages 123-131

  Barten, Markus J ^a   Shipkova, Maria ^b   Bartsch, Peter ^a   Dhein, Stefan ^a   Streit, Frank ^c   Tarnok, Attila ^a   Armstrong, Victor W ^c   Mohr, Friederich W ^a   Oellerich, Michael ^c   Gummert, Jan F ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b KLINIKUM STUTTGART   (Germany)

^c UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

Cylosporine; Flow cytometry; Immunosuppression; Lymphocyte function; Mycophenolic acid; Pharmacodynamic; Pharmacokinetic; Tacrolimus

Indexed keywords

CYCLINE; CYCLOSPORIN A; INTERLEUKIN 2 RECEPTOR ALPHA; MYCOPHENOLIC ACID; TACROLIMUS;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; DRUG MECHANISM; DRUG POTENTIATION; FLOW CYTOMETRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE FUNCTION; LYMPHOCYTE PROLIFERATION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; T LYMPHOCYTE ACTIVATION;

ADMINISTRATION, ORAL; ANIMALS; AREA UNDER CURVE; CELL PROLIFERATION; CYCLOSPORINE; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; LYMPHOCYTES; MEN; MYCOPHENOLIC ACID; RATS; RATS, INBRED LEW; RECEPTORS, INTERLEUKIN-2; TACROLIMUS;

EID: 20144389344     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ftd.0000146874.11480.8a     Document Type: Article

References (41)

1. Kahan BD, Koch SM. Current immunosuppressant regimens: considerations for critical care. Curr Opin Crit Care. 2001;7:242-250.
2. Hibbins M, Inutsuka S, Chapman JR. Inhibition of PHA induced mononuclear cell proliferation by FK506 in combination with cyclosporine, methylprednisolone, 6-mercaptopurine and mycophenolic acid. Transpl Immunol. 1993;1:66-71.
3. Thomson AW, Woo J, Yao GZ, et al. Effects of combined administration of FK 506 and the purine biosynthesis inhibitors mizoribine or mycophenolic acid on lymphocyte DNA synthesis and T cell activation molecule expression in human mixed lymphocyte cultures. Transpl Immunol. 1993;1:146-150.
4. Weaver JL, Pine PS, Aszalos A. Comparison of the in vitro and biophysical effects of cyclosporine A, FK-506, and mycophenolic acid on human peripheral blood lymphocytes. Immunopharmacol Immunotoxicol. 1991;13:563-576.
5. + human lymphocytes. Transplant Proc. 1991;23:2939-2940.
6. Zeevi A, Woan M, Yao GZ, et al. Comparative in vitro studies on the immunosuppressive activities of mycophenolic acid, bredinin, FK 506, cyclosporine, and rapamycin. Transplant Proc. 1991;23:2928-2930.
7. Armstrong VW, Oellerich M. New developments in the immunosuppressive drug monitoring of cyclosporine, tacrolimus, and azathioprine. Clin Biochem. 2001;34:9-16.
8. Shaw LM, Holt DW, Oellerich M, et al. Current issues in therapeutic drug monitoring of mycophenolic acid: Report of a roundtable discussion. Ther Drug Monit. 2001;23:305-315.
9. Gregoor PJ, de Sevaux RG, Hene RJ, et al. Effect of cyclosporine on mycophenolic acid trough levels in kidney transplant recipients. Transplantation. 1999;68:1603-1606.
10. van Gelder T, Klupp J, Barten MJ, et al. Comparison of the effects of tacrolimus and cyclosporine on the pharmacokinetics of mycophenolic acid. Ther Drug Monit. 2001;23:119-128.
11. Zucker K, Rosen A, Tsaroucha A, et al. Augmentation of mycophenolate mofetil pharmacokinetics in renal transplant patients receiving prograf and cellcept in combination therapy. Transplant Proc. 1997;29:334-336.
12. Dambrin C, Klupp J, Morris RE. Pharmacodynamics of immunosuppressive drugs. Curr Opin Immunol. 2000;12:557-562.
13. Bloemena E, Koopmans RP, Weinreich S, et al. Pharmacodynamic modeling of lymphocytopenia and whole blood lymphocyte cultures in prednisolone-treated individuals. Clin Immunol Immunopathol. 1990;57: 374-386.
14. Magee MH, Blum RA, Lates CD, et al. Pharmacokinetic/pharmacodynamic model for prednisolone inhibition of whole blood lymphocyte proliferation. Br J Clin Pharmacol. 2002;53:474-484.
15. Wiegers GJ, Croiset G, Reul JM, et al. Differential effects of corticosteroids on rat peripheral blood T-lymphocyte mitogenesis in vivo and in vitro. Am J Physiol. 1993;265:E825-E830.
16. Batiuk TD, Pazderka F, Halloran PF. Calcineurin activity is only partially inhibited in leukocytes of cyclosporine treated patients. Transplantation. 1995;59:1400-1404.
17. Halloran PF, Helms LM, Kung L, et al. The temporal profile of calcineurin inhibition by cyclosporine in vivo. Transplantation. 1999;68:1356-1361.
18. Langman LJ, Le GD, Halloran PF, et al. Pharmacodynamic assessment of mycophenolic acid-induced immunosuppression in renal transplant recipients. Transplantation. 1996;62:666-672.
19. Weigel G, Griesmacher A, Zuckermann AO, et al. Effect of mycophenolate mofetil therapy on inosine monophosphate dehydrogenase induction in red blood cells of heart transplant recipients. Clin Pharmacol Ther. 2001;69:137-144.
20. Ahmed M, Venkataraman R, Logar AJ, et al. Quantitation of immunosuppression by tacrolimus using flow cytometric analysis of interleukin-2 and interferon-gamma inhibition in CD8(-) and CD8(+) peripheral blood T cells. Ther Drug Monit. 2001;23:354-362.
21. Chen YW, Smith ML, Sheets MP, et al. Ex vivo assessment of immunosuppression in undiluted whole blood from pigs dosed with tacrolimus (FK506). Clin Immunol. 1999;90:133-140.
22. van den Berg AP, Twilhaar WN, Mesander G, et al. Quantitation of immunosuppression by flow cytometric measurement of the capacity of T cells for interleukin-2 production. Transplantation. 1998;65:1066-1071.
23. Stalder M, Birsan T, Holm B, et al. Quantification of immunosuppression by flow cytometry in stable renal transplant recipients. Ther Drug Monit. 2003;25:22-27.
24. Weigel G, Griesmacher A, Karimi A, et al. Effect of mycophenolate mofetil therapy on lymphocyte activation in heart transplant recipients. J Heart Lung Transplant. 2002;21:1074-1079.
25. Hartel C, Fricke L, Schumacher N, et al. Delayed cytokine mRNA expression kinetics after T-lymphocyte costimulation: a quantitative measure of the efficacy of cyclosporin A-based immunosuppression. Clin Chem. 2002;48:2225-2231.
26. Barten MJ, Gummert JF, van Gelder T, et al. Flow cytometric quantitation of calcium-dependent and -independent mitogen-stimulation of T cell functions in whole blood: inhibition by immunosuppressive drugs in vitro. J Immunol Methods. 2001;253:95-112.
27. Gummert JF, Barten MJ, Sherwood SW. et al. Pharmacodynamics of immunosuppression by mycophenolic acid: inhibition of both lymphocyte proliferation and activation correlates with pharmacokinetics. J Pharmacol Exp Ther. 1999;291:1100-1112.
28. Barten MJ, van Gelder T, Gummert JF, et al. Novel assays of multiple lymphocyte functions in whole blood measure: new mechanisms of action of mycophenolate mofetil in vivo. Transpl Immunol. 2002;10:1-14.
29. Barten MJ, van Gelder T. Gummert JF, et al. Pharmacodynamics of mycophenolate mofetil after heart transplantation: new mechanisms of action and correlations with histologic severity of graft rejection. Am J Transplant. 2002;2:719-732.
30. Barten MJ, Streit F, Boeger M, et al. Synergistic effects of sirolimus with cyclosporine and tacrolimus: Analysis of immunosuppression on lymphocyte proliferation and activation in rat whole blood. Transplantation. 2004;77:1154-1162.
31. Gummert JF, Otto G, Barten MJ, et al. Effect of anesthesia on a whole blood lymphocyte proliferation assay in the rat. Immunopharmacol Immunotoxicol. 1999;21:267-276.
32. Woo J, Roos CS, Milton JI, et al. Flow cytometric analysis of lymphocyte populations and activation antigen expression in blood and lymphoid tissues of FK 506-treated rats. Transplant Proc. 1990;22:1642-1644.
33. Shipkova M, Niedmann PD, Armstrong VW, et al. Simultaneous determination of mycophenolic acid and its glucuronide in human plasma using a simple high-performance liquid chromatography procedure. Clin Chem. 1998;44:1481-1488.
34. Streit F, Armstrong VW, Oellerich M. Rapid liquid chromatography-tandem mass spectrometry routine method for simultaneous determination of sirolimus, everolimus, tacrolimus, and cyclosporin A in whole blood. Clin Chem. 2002;48:955-958,
35. Poch G, Schmidt K, Dittrich P. Evaluation of the type of overadditive drug interaction under various experimental conditions: differentiation of sequential from functional synergism in dose response studies. Methods Findings Exp Clin Pharmacol. 1982a;4:371.
36. Poch G, Holzmann S, Bradacs H. Evaluation and interpretation of dose response experiments with decreased baseline. Methods Findings Exp Clin Pharmacol. 1982b;4:379.
37. Levy GA. Long-term immunosuppression and drug interactions. Liver Transpl. 2001;7:S53-S59.
38. 2 estimation of partial agonists: comparison with the Kaumann-Blinks method. J Pharmacol Methods. 1988;19:47-56.
39. Kahan BD. Tejpal N, Gibbons-Stubbers S, et al. The synergistic interactions in vitro and in vivo of brequinar sodium with cyclosporine or rapamycin alone and in triple combination. Transplantation. 1993;55:894-900.
40. Kung L, Halloran PF. Immunophilins may limit calcineurin inhibition by cyclosporine and tacrolimus at high drug concentrations. Transplantation. 2000;70:327-335.
41. Barten MJ, Dhein S, Chang H, et al. Assessment of immunosuppressive drug interactions: inhibition of lymphocyte function in peripheral human blood. J Immunol Methods. 2003;283:99-114.